These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

389 related articles for article (PubMed ID: 28301631)

  • 1. Androgen Receptor Function and Androgen Receptor-Targeted Therapies in Breast Cancer: A Review.
    Kono M; Fujii T; Lim B; Karuturi MS; Tripathy D; Ueno NT
    JAMA Oncol; 2017 Sep; 3(9):1266-1273. PubMed ID: 28301631
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Androgen Receptor in Breast Cancer-Clinical and Preclinical Research Insights.
    Anestis A; Zoi I; Papavassiliou AG; Karamouzis MV
    Molecules; 2020 Jan; 25(2):. PubMed ID: 31952272
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Synergy between inhibitors of androgen receptor and MEK has therapeutic implications in estrogen receptor-negative breast cancer.
    Naderi A; Chia KM; Liu J
    Breast Cancer Res; 2011 Apr; 13(2):R36. PubMed ID: 21457548
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Androgen Receptor as an Emerging Feasible Biomarker for Breast Cancer.
    You CP; Leung MH; Tsang WC; Khoo US; Tsoi H
    Biomolecules; 2022 Jan; 12(1):. PubMed ID: 35053220
    [TBL] [Abstract][Full Text] [Related]  

  • 5. PIK3CA mutations in androgen receptor-positive triple negative breast cancer confer sensitivity to the combination of PI3K and androgen receptor inhibitors.
    Lehmann BD; Bauer JA; Schafer JM; Pendleton CS; Tang L; Johnson KC; Chen X; Balko JM; Gómez H; Arteaga CL; Mills GB; Sanders ME; Pietenpol JA
    Breast Cancer Res; 2014 Aug; 16(4):406. PubMed ID: 25103565
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The role of the androgen receptor in triple-negative breast cancer.
    Shah PD; Gucalp A; Traina TA
    Womens Health (Lond); 2013 Jul; 9(4):351-60. PubMed ID: 23826776
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Role of PI3K-AKT-mTOR Pathway as a Pro-Survival Signaling and Resistance-Mediating Mechanism to Therapy of Prostate Cancer.
    Pungsrinont T; Kallenbach J; Baniahmad A
    Int J Mol Sci; 2021 Oct; 22(20):. PubMed ID: 34681745
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Androgen receptor expression in breast cancer: Implications on prognosis and treatment, a brief review.
    Jahan N; Jones C; Rahman RL
    Mol Cell Endocrinol; 2021 Jul; 531():111324. PubMed ID: 34000352
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Androgen receptor signaling pathways as a target for breast cancer treatment.
    Pietri E; Conteduca V; Andreis D; Massa I; Melegari E; Sarti S; Cecconetto L; Schirone A; Bravaccini S; Serra P; Fedeli A; Maltoni R; Amadori D; De Giorgi U; Rocca A
    Endocr Relat Cancer; 2016 Oct; 23(10):R485-98. PubMed ID: 27528625
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Reciprocal feedback inhibition of the androgen receptor and PI3K as a novel therapy for castrate-sensitive and -resistant prostate cancer.
    Qi W; Morales C; Cooke LS; Johnson B; Somer B; Mahadevan D
    Oncotarget; 2015 Dec; 6(39):41976-87. PubMed ID: 26506516
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The Role of the Androgen Receptor Signaling in Breast Malignancies.
    Christopoulos PF; Vlachogiannis NI; Vogkou CT; Koutsilieris M
    Anticancer Res; 2017 Dec; 37(12):6533-6540. PubMed ID: 29187427
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Synergy between Androgen Receptor Antagonism and Inhibition of mTOR and HER2 in Breast Cancer.
    Gordon MA; D'Amato NC; Gu H; Babbs B; Wulfkuhle J; Petricoin EF; Gallagher I; Dong T; Torkko K; Liu B; Elias A; Richer JK
    Mol Cancer Ther; 2017 Jul; 16(7):1389-1400. PubMed ID: 28468774
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Androgen Receptor Biology in Triple Negative Breast Cancer: a Case for Classification as AR+ or Quadruple Negative Disease.
    Barton VN; D'Amato NC; Gordon MA; Christenson JL; Elias A; Richer JK
    Horm Cancer; 2015 Dec; 6(5-6):206-13. PubMed ID: 26201402
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Androgen Receptor Expression and Bicalutamide Antagonize Androgen Receptor Inhibit β-Catenin Transcription Complex in Estrogen Receptor-Negative Breast Cancer.
    Huang R; Han J; Liang X; Sun S; Jiang Y; Xia B; Niu M; Li D; Zhang J; Wang S; Wei W; Liu Q; Zheng W; Zhang G; Song Y; Panga D
    Cell Physiol Biochem; 2017; 43(6):2212-2225. PubMed ID: 29069648
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The PI3K-AKT-mTOR Pathway and Prostate Cancer: At the Crossroads of AR, MAPK, and WNT Signaling.
    Shorning BY; Dass MS; Smalley MJ; Pearson HB
    Int J Mol Sci; 2020 Jun; 21(12):. PubMed ID: 32630372
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Impact of androgen receptor expression in fluoxymesterone-treated estrogen receptor-positive metastatic breast cancer refractory to contemporary hormonal therapy.
    Kono M; Fujii T; Lyons GR; Huo L; Bassett R; Gong Y; Karuturi MS; Tripathy D; Ueno NT
    Breast Cancer Res Treat; 2016 Nov; 160(1):101-109. PubMed ID: 27663436
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Consideration of breast cancer subtype in targeting the androgen receptor.
    Venema CM; Bense RD; Steenbruggen TG; Nienhuis HH; Qiu SQ; van Kruchten M; Brown M; Tamimi RM; Hospers GAP; Schröder CP; Fehrmann RSN; de Vries EGE
    Pharmacol Ther; 2019 Aug; 200():135-147. PubMed ID: 31077689
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Androgen blockade based clinical trials landscape in triple negative breast cancer.
    Shi Y; Yang F; Huang D; Guan X
    Biochim Biophys Acta Rev Cancer; 2018 Dec; 1870(2):283-290. PubMed ID: 29807045
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Androgen receptor variant-driven prostate cancer: clinical implications and therapeutic targeting.
    Antonarakis ES; Armstrong AJ; Dehm SM; Luo J
    Prostate Cancer Prostatic Dis; 2016 Sep; 19(3):231-41. PubMed ID: 27184811
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Combination effect of therapies targeting the PI3K- and AR-signaling pathways in prostate cancer.
    Yadav SS; Li J; Stockert JA; O'Connor J; Herzog B; Elaiho C; Galsky MD; Tewari AK; Yadav KK
    Oncotarget; 2016 Nov; 7(46):76181-76196. PubMed ID: 27783994
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.